Reply to: In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors

Ravin Ratan¹, Bernd Kasper¹, Thierry Alcindor¹+14

• ¹Ravin Ratan, MD, MEd, Division of Cancer Medicine, Department of Sarcoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX; Bernd Kasper, MD, PhD, Sarcoma Unit, Mannheim University Medical Center, Mannheim Cancer Center, University of Heidelberg, Mannheim, Germany; Thierry Alcindor, MD, MS, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; Patrick Schöffski, MD, Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium; Winette T. van der Graaf, MD, PhD, Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Noah Federman, MD, Departments of Pediatrics and Orthopedics, UCLA Jonsson Comprehensive Cancer Center, UCLA David Geffen School of Medicine, Los Angeles, CA; Nam Q. Bui, MD, Division of Oncology, Department of Medicine, Stanford University, Stanford, CA; Gina D'Amato, MD, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL; Richard F. Riedel, MD, Duke Cancer Institute, Duke University Medical Center, Durham, NC; Steven Attia, DO, Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL; Sant Chawla, MD, Sarcoma Oncology Center, Santa Monica, CA; Allison Lim, PharmD; Brad Tumminello, PharmD, and Ana B. Oton, MD, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; Yucheng Chu, MS, Sumptuous Data Sciences, Monmouth Junction, NJ; Shengfan Zhou, MS, SpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; and Mrinal Gounder, MD, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.